Editorial
One more time, I have to start our conversation by drawing attention to serious risks that are being imposed on the health and the health law in Brazil today. Unfortunately we live in a time of distrust on institutions, a scenario where profiteers of all kinds flourish. This is what is happening now...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2016-03-01
|
| Series: | Revista de Direito Sanitário |
| Subjects: | |
| Online Access: | http://www.revistas.usp.br/rdisan/article/view/117040/114707 |
| id |
doaj-df89e64bcb8f43f894f9c0dcec85bd6c |
|---|---|
| record_format |
Article |
| spelling |
doaj-df89e64bcb8f43f894f9c0dcec85bd6c2020-11-24T22:48:55ZengUniversidade de São PauloRevista de Direito Sanitário1516-41792316-90442016-03-0117171310.11606/issn.2316-9044.v17i1p7-13EditorialDALLARI, Sueli Gandolfi0Universidade de São Paulo, São Paulo, SP, BrazilOne more time, I have to start our conversation by drawing attention to serious risks that are being imposed on the health and the health law in Brazil today. Unfortunately we live in a time of distrust on institutions, a scenario where profiteers of all kinds flourish. This is what is happening now with the health legislation in the Brazilian Congress. On April 13, 2016, Brazilian Federal Law n. 13269 was enacted, without vetoes, authorizing patients with cancer to be cared with the synthetic substance phosphoethanolamine. And on April 20, 2016, the Brazilian Federal Senate approved the production and sale of weight-loss drugs containing sibutramine, amfepramone, fenproporex and mazindol. In both cases, the Brazilian National Health Surveillance Agency (Anvisa) ‒ responsible for the registration of medicines, ensuring their quality, safety and efficacy ‒ had spoken unfavorably.http://www.revistas.usp.br/rdisan/article/view/117040/114707Editorial |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
DALLARI, Sueli Gandolfi |
| spellingShingle |
DALLARI, Sueli Gandolfi Editorial Revista de Direito Sanitário Editorial |
| author_facet |
DALLARI, Sueli Gandolfi |
| author_sort |
DALLARI, Sueli Gandolfi |
| title |
Editorial |
| title_short |
Editorial |
| title_full |
Editorial |
| title_fullStr |
Editorial |
| title_full_unstemmed |
Editorial |
| title_sort |
editorial |
| publisher |
Universidade de São Paulo |
| series |
Revista de Direito Sanitário |
| issn |
1516-4179 2316-9044 |
| publishDate |
2016-03-01 |
| description |
One more time, I have to start our conversation by drawing attention to serious risks that are being imposed on the health and the health law in Brazil today. Unfortunately we live in a time of distrust on institutions, a scenario where profiteers of all kinds flourish. This is what is happening now with the health legislation in the Brazilian Congress. On April 13, 2016, Brazilian Federal Law n. 13269 was enacted, without vetoes, authorizing patients with cancer to be cared with the synthetic substance phosphoethanolamine. And on April 20, 2016, the Brazilian Federal Senate approved the production and sale of weight-loss drugs containing sibutramine, amfepramone, fenproporex and mazindol. In both cases, the Brazilian National Health Surveillance Agency (Anvisa) ‒ responsible for the registration of medicines, ensuring their quality, safety and efficacy ‒ had spoken unfavorably. |
| topic |
Editorial |
| url |
http://www.revistas.usp.br/rdisan/article/view/117040/114707 |
| work_keys_str_mv |
AT dallarisueligandolfi editorial |
| _version_ |
1725678087440433152 |